FDA Clears Breztri for Asthma Use - Summary - MDSpire

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.

  • By

  • Kathryn Wighton

  • April 28, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of a new inhaled therapy for asthma maintenance treatment.

Key Findings:
  • Significant improvement in forced expiratory volume within 3 hours at 24 weeks.
  • Improvements in trough lung function over 12 to 24 weeks.
  • No new safety or tolerability concerns identified.
Interpretation:

The approval of Breztri addresses the needs of asthma patients who remain uncontrolled on dual therapies, potentially reducing exacerbations and improving daily breathing.

Limitations:
  • Not intended for acute bronchospasm relief or as a substitute for rescue inhalers.
  • Limited to patients aged 12 years and older.
Conclusion:

Breztri offers a new maintenance treatment option for asthma, expanding its use beyond chronic obstructive pulmonary disease.

Original Source(s)

FDA Clears Breztri for Asthma Use

  • by Kathryn Wighton

  • April 28, 2026

Related Content

Shorter TB Regimens Advance Care

Review highlights shorter tuberculosis regimens while warning that rising bedaquiline resistance may threaten future progress.

ACS Collaborative May Improve Compliance in Lung Nodal Assessment

Community programs showed the largest gains in compliance with a surgical staging standard following participation in the Lung NODES collaborative.

Comparative efficacy of single exercise interventions on pulmonary function and quality of life in patients with chronic obstructive pulmonary disease: a systematic review and network meta-analysis